Overview of the Conference Participation
Aquestive Therapeutics, Inc., a leading pharmaceutical company focused on advancing innovative medicines to improve patient outcomes, has announced its participation in the prestigious Oppenheimer 36th Annual Healthcare Life Sciences Conference. This highly anticipated virtual event is scheduled to take place on February 25–26, bringing together top healthcare and life sciences companies with institutional investors and industry analysts from around the globe.
The conference serves as a key platform for pharmaceutical and biotech firms to share their corporate vision, product development progress, and growth strategies directly with the investment community. Aquestive’s decision to participate underscores its commitment to transparency and investor engagement at a critical stage of its pipeline development.
Presentation Details and Schedule
When and How to Tune In
Aquestive’s management team will deliver a formal presentation on February 26th at 12:00 PM ET. The session is expected to provide attendees with an in-depth look at the company’s current strategy, ongoing clinical programs, and its broader vision for transforming medication delivery through proprietary science and film-based technologies.
One-on-One Investor Meetings
In addition to the main presentation, Aquestive’s leadership will also conduct private one-on-one meetings with investors on the same day. These sessions offer institutional investors and analysts a unique opportunity to engage directly with management, ask targeted questions, and gain deeper insights into the company’s financial outlook and pipeline progress. Such meetings are an essential part of building investor confidence and strengthening relationships within the financial community.
Webcast Access and Replay Information
Live and On-Demand Viewing Options
A live webcast of the presentation will be made available through the “Events and Presentations” section located within the Investors area of Aquestive’s official website. Investors and interested stakeholders who are unable to attend the live session need not worry — a full replay of the webcast will remain accessible for 30 days following the conclusion of the event, ensuring broad access to all relevant information shared during the conference.
For complete event details, registration links, and additional resources, visitors are encouraged to go directly to investors.aquestive.com.
About Aquestive Therapeutics
A Pioneer in Oral Film Drug Delivery
Aquestive Therapeutics is recognized as the worldwide leader in delivering trusted, quality medications via oral film. The company operates a dual business model — functioning both as a developer of its own proprietary pharmaceutical products and as a Contract Development and Manufacturing Organization (CDMO) serving a range of licensees globally.
Headquartered in New Jersey, with U.S.-based manufacturing facilities in Indiana, Aquestive brings a unique combination of commercial-stage experience and innovative drug development to the pharmaceutical landscape. The company’s products and technologies are currently marketed across six continents, reflecting its strong international footprint.
Aquestive is the exclusive manufacturer of four commercialized products licensed to partners worldwide, all leveraging the company’s proprietary, best-in-class drug delivery technologies.
Key Pipeline Products and Innovations
Anaphylm™ — A Breakthrough in Anaphylaxis Treatment
One of Aquestive’s most promising pipeline assets is Anaphylm™ (dibutepinephrine) sublingual film, currently in development for the treatment of severe allergic reactions, including anaphylaxis. This product is part of the broader AdrenaVerse™ platform, which contains a library of more than 20 epinephrine prodrugs targeting a wide array of allergy and dermatological indications.
AQST-108 Topical Gel for Dermatological Conditions
Another key pipeline candidate is AQST-108 (epinephrine prodrug) topical gel, being investigated for various dermatological conditions, including alopecia areata. If successfully developed, this product could open new therapeutic avenues for patients suffering from complex skin and hair-related disorders that currently have limited treatment options.
PharmFilm® Technology and CDMO Operations
Setting the Standard in Oral Film Technology
At the heart of Aquestive’s commercial success is its patented PharmFilm® technology, a best-in-class oral film drug delivery system. This proprietary platform has been instrumental in enabling the commercialization of multiple products marketed by Aquestive’s licensees worldwide. PharmFilm® represents a significant competitive advantage that positions Aquestive as a preferred manufacturing and development partner in the global pharmaceutical industry.
As a CDMO, Aquestive offers an end-to-end service model — from formulation development and clinical manufacturing to commercial-scale production — allowing pharmaceutical partners to leverage its advanced capabilities without the need to build independent infrastructure.
